Ziel
The world is facing an antibiotics crisis, with resistant bacteria rendering current treatments ineffective. Novel, effective solutions are urgently required for this $40bn global market. Westway Health (WWH) is based in Galway, Ireland, and is on track to become a leading veterinary antimicrobials company in the EU. It has developed an innovative, non-antibiotic technology, effective at killing all bacteria, including antibiotic-resistant bacteria like MRSA, while not inducing resistance. WWH’s lead product in development is PanaMastTM LC, a breakthrough treatment of bovine mastitis, the most economically important infectious disease affecting the dairy industry. PanaMastTM LC will represent a step change in the way that dairy farmers manage mastitis, which affects 30% of the herd annually. It will: 1. Be the world’s first non-antibiotic medicine for mastitis, offering superior clinical outcomes and significant financial gains to end-users (€150/case); 2. Reduce wastage of milk and culling of cows; (3) Improve profitability and environmental performance on European farms and dairy processing sites. The innovation directly addresses the major global problem of antibiotic resistance, while providing a sustainable animal health solution that supports production of safe and high quality food. The Phase 1 PanaMast project was successfully completed ahead of schedule and on budget. It allowed WWH to: 1. Develop a regulatory roadmap detailing all steps required to progress from current stage of development (TRL7) to first sale of commercial product (TRL8); 2. Develop a robust commercial exploitation plan for PanaMastTM LC in EU and global markets; 3. Establish key strategic relationships to assist commercialisation of PanaMastTM LC
The Phase 1 results underpin this proposed project. The Phase 2 activities (pre-commercialisation/product development/product launch and commercialisation) are designed to ensure market launch and sale of PanaMastTM LC in the EU at TRL8 by 2020
Wissenschaftliches Gebiet
CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.
CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.
- natural sciencesbiological sciencesmicrobiologybacteriology
- agricultural sciencesanimal and dairy sciencedairy
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Schlüsselbegriffe
Programm/Programme
- H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
- H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy
- H2020-EU.3.2.1. - Sustainable agriculture and forestry
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SMEINST-2-2016-2017
Finanzierungsplan
SME-2 - SME instrument phase 2Koordinator
H91 Galway
Irland
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).